170 related articles for article (PubMed ID: 20538761)
1. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma.
Hwang JJ; Kuruvilla J; Mendelson D; Pishvaian MJ; Deeken JF; Siu LL; Berger MS; Viallet J; Marshall JL
Clin Cancer Res; 2010 Aug; 16(15):4038-45. PubMed ID: 20538761
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.
Paik PK; Rudin CM; Brown A; Rizvi NA; Takebe N; Travis W; James L; Ginsberg MS; Juergens R; Markus S; Tyson L; Subzwari S; Kris MG; Krug LM
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1079-85. PubMed ID: 20165849
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.
O'Brien SM; Claxton DF; Crump M; Faderl S; Kipps T; Keating MJ; Viallet J; Cheson BD
Blood; 2009 Jan; 113(2):299-305. PubMed ID: 18931344
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
Chiappori AA; Schreeder MT; Moezi MM; Stephenson JJ; Blakely J; Salgia R; Chu QS; Ross HJ; Subramaniam DS; Schnyder J; Berger MS
Br J Cancer; 2012 Feb; 106(5):839-45. PubMed ID: 22333598
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.
Parikh SA; Kantarjian H; Schimmer A; Walsh W; Asatiani E; El-Shami K; Winton E; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):285-9. PubMed ID: 20709666
[TBL] [Abstract][Full Text] [Related]
6. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.
Chiappori A; Williams C; Northfelt DW; Adams JW; Malik S; Edelman MJ; Rosen P; Van Echo DA; Berger MS; Haura EB
J Thorac Oncol; 2014 Jan; 9(1):121-5. PubMed ID: 24346101
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
Schimmer AD; O'Brien S; Kantarjian H; Brandwein J; Cheson BD; Minden MD; Yee K; Ravandi F; Giles F; Schuh A; Gupta V; Andreeff M; Koller C; Chang H; Kamel-Reid S; Berger M; Viallet J; Borthakur G
Clin Cancer Res; 2008 Dec; 14(24):8295-301. PubMed ID: 19088047
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
13. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.
Oki Y; Copeland A; Hagemeister F; Fayad LE; Fanale M; Romaguera J; Younes A
Blood; 2012 Mar; 119(9):2171-2. PubMed ID: 22383790
[No Abstract] [Full Text] [Related]
14. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
16. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.
Schimmer AD; Raza A; Carter TH; Claxton D; Erba H; DeAngelo DJ; Tallman MS; Goard C; Borthakur G
PLoS One; 2014; 9(10):e108694. PubMed ID: 25285531
[TBL] [Abstract][Full Text] [Related]
17. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors.
Giantonio BJ; Derry C; McAleer C; McPhillips JJ; O'Dwyer PJ
Clin Cancer Res; 2004 Feb; 10(4):1282-8. PubMed ID: 14977826
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.
Holen K; DiPaola R; Liu G; Tan AR; Wilding G; Hsu K; Agrawal N; Chen C; Xue L; Rosenberg E; Stein M
Invest New Drugs; 2012 Jun; 30(3):1088-95. PubMed ID: 21424701
[TBL] [Abstract][Full Text] [Related]
20. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
